The Latest Breaking News from Amedisys

Why Is UnitedHealth Stock Trading Higher Friday?

UnitedHealth Group Inc. (NYSE:UNH) shares climbed Friday after high-profile investors Michael Burry and Warren Buffett took positions in the insurance giant, offering some relief to a stock that has tumbled about 41% year-to-date.

Benzinga · Aug 15, 2025

What's Going On With UnitedHealth Stock Monday?

UnitedHealth Group Inc. (NYSE:UNH) shares edged up on Monday, even as the stock remains down roughly 49% year to date. Trading volume stood at 6.39 million shares, well below the 100-day average of 20.28 million, according to Benzinga Pro. No fresh catalysts were apparent for Monday's move.

Benzinga · Aug 11, 2025

UnitedHealth Faces Large Outpatient Divestiture To Resolve Antitrust Suit Related To Amedisys Deal

UnitedHealth Group Inc. (NYSE:UNH) would divest more than 160 healthcare facilities as part of a proposed settlement with the U.S. Department of Justice (DOJ) to resolve antitrust concerns surrounding its $3.3 billion acquisition of Amedisys Inc. (NASDAQ:AMED).

Benzinga · Aug 8, 2025

Justice Department sues to block UnitedHealth Group's $3.3 billion purchase of Amedisys

The Justice Department is suing to block UnitedHealth Group’s $3.3 billion purchase of Amedisys

The Independent UK · Nov 12, 2024

UnitedHealth buying home health care provider in $3.3B deal

UnitedHealth Group has struck a deal to acquire home health care provider Amedisys Inc. for $3.3 billion in an all-cash deal.

Tribune News Service · Jun 27, 2023

Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2022

Upgrades

Benzinga · Oct 27, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022

Upgrades

Benzinga · Aug 2, 2022

Stephens & Co. Maintains Equal-Weight Rating for Amedisys: Here's What You Need To Know

Stephens & Co. has decided to maintain its Equal-Weight rating of Amedisys (NASDAQ:AMED) and lower its price target from $155.00 to $125.00. Shares of Amedisys are trading down 12.59% over the last 24 hours, at $106.09 per share.

Benzinga · Jun 21, 2022

Analyst Ratings for Amedisys

Analysts have provided the following ratings for Amedisys (NASDAQ:AMED) within the last quarter:

Benzinga · Jun 21, 2022

Analyst Ratings for Amedisys

Over the past 3 months, 5 analysts have published their opinion on Amedisys (NASDAQ:AMED) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · May 27, 2022